February 13th 2025
The company plans to assess alternate payloads for its gene therapy program, which will shift its timeline.
Accurately targeted immunotherapies through reliable neoantigen recognition enable personalized medicine development.
Quality by Design for Biotechnology Products—Part 3
Regulatory flexibility can make continuous improvement possible.
Quality by Design for Biotechnology Products—Part 2
Second in a three-part series that discusses the complexities of QbD implementation in biotech development.
High-Cell-Density Culture to Produce Plasmid DNA for Gene Therapy in E. coli
How to produce Plasmid DNA in a high-cell-density culture.